New agents for Gram-positive bacteria

Infections caused by multiple-resistant Gram-positive organisms continue to occur at an alarming rate worldwide. Two new and unique antimicrobial agents targeted specifically against such organisms, quinupristin/dalfopristin and linezolid, have been approved for use in the USA in the past year and w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current Opinion in Microbiology 2000-10, Vol.3 (5), p.528-534
Hauptverfasser:	Bhavnani, Sujata M, Ballow, Charles H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetamides - therapeutic use AECB acute exacerbations of chronic bronchitis AMS acute maxillary sinusitis Anti-Bacterial Agents - therapeutic use CAP community-acquired pneumonia Clinical Trials as Topic dalfopristin Drug Approval Fluoroquinolones Glycopeptides Gram-Positive Bacterial Infections - drug therapy Humans Linezolid MIC minimum inhibitory concentration Oxazolidinones - therapeutic use Q/D quinupristin/dalfopristin quinupristin Streptococcus pneumoniae Virginiamycin - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!